ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 05/01/23

2023-05-01 23:53:08 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Arrowhead Pharmaceuticals and Meta propelled my portfolio again to all-time highs and mar...

2023-04-28 13:30:26 ET Earnings season keeps running at pace during the first week of May, with reports due from numerous leaders in the semiconductor, auto, pharmaceuticals, energy, software and media industries. The week is also dotted with earnings updates from consumer packaged goods co...

2023-04-25 11:20:36 ET Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial. Arrowhead's shares are down more than 13% this year but up more tha...

2023-04-25 10:43:30 ET Arrowhead Pharma ( NASDAQ: ARWR ) is trading ~16.4% higher after it announced interim results from an ongoing Phase 1/2 study of RNAi therapeutic, ARO-RAGE, to reduce production of the receptor for advanced glycation end products (RAGE) as a potential tr...

2023-04-25 10:06:07 ET Gainers: Baudax Bio ( BXRX ) +48% . Petros Pharmaceuticals ( PTPI ) +48% . Morphic Holding ( MORF ) +22% . Arrowhead Pharmaceuticals ( ARWR ) +17% . Medpace Holdings ( MEDP ) +17% . Losers: Trac...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) +74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) +34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) +32% . ZeroFox ...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) -74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) -34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) -32% . ZeroFox ...

- Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses - Further Data to be Presented at Upcoming R&D Day Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results f...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...